Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas W Flaig

Showing results (1-10 of 141) with videos related to

Pageof 15
Sort By:
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2019
NCCN Guidelines Updates: Management of Muscle-Invasive Bladder CancerThomas W Flaig
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2018
The Changing Treatment Landscape for Metastatic Urothelial CarcinomaThomas W Flaig
Nature Reviews. Urology|December 22, 2011
Bladder cancer in 2011: the dawn of personalized medicineThomas W Flaig, Dan Theodorescu
Advances in Urology|March 31, 2012
Redefining hormone sensitive disease in advanced prostate cancerXiaoyu Hou, Thomas W Flaig
European Urology|May 30, 2012
Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 statusThomas W Flaig, Dan Theodorescu
International Braz J Urol : Official Journal of the Brazilian Society of Urology|July 7, 2010
Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical applicationXiaoping Yang, Thomas W Flaig
Oncology (Williston Park, N.Y.)|January 12, 2019
Point-Prostate Cancer Genomic Analysis: Routine or Research Only?Brandon Bernard, Thomas W Flaig
Expert Opinion on Pharmacotherapy|December 2, 2010
Adjuvant medical therapy for prostate cancerChristopher Sumey, Thomas W Flaig
Oncology (Williston Park, N.Y.)|February 8, 2011
A renaissance in the medical treatment of advanced prostate cancerKyle O Rove, Thomas W Flaig
Current Drug Targets|June 6, 2015
The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial CarcinomaMaria T Bourlon, Thomas W Flaig
Pageof 15

Showing results (1-10 of 141) with videos related to

Sort By:
Pageof 15
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2019
NCCN Guidelines Updates: Management of Muscle-Invasive Bladder CancerThomas W Flaig
Journal of the National Comprehensive Cancer Network : JNCCN|May 23, 2018
The Changing Treatment Landscape for Metastatic Urothelial CarcinomaThomas W Flaig
Nature Reviews. Urology|December 22, 2011
Bladder cancer in 2011: the dawn of personalized medicineThomas W Flaig, Dan Theodorescu
Advances in Urology|March 31, 2012
Redefining hormone sensitive disease in advanced prostate cancerXiaoyu Hou, Thomas W Flaig
European Urology|May 30, 2012
Words of wisdom. Re: Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 statusThomas W Flaig, Dan Theodorescu
International Braz J Urol : Official Journal of the Brazilian Society of Urology|July 7, 2010
Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical applicationXiaoping Yang, Thomas W Flaig
Oncology (Williston Park, N.Y.)|January 12, 2019
Point-Prostate Cancer Genomic Analysis: Routine or Research Only?Brandon Bernard, Thomas W Flaig
Expert Opinion on Pharmacotherapy|December 2, 2010
Adjuvant medical therapy for prostate cancerChristopher Sumey, Thomas W Flaig
Oncology (Williston Park, N.Y.)|February 8, 2011
A renaissance in the medical treatment of advanced prostate cancerKyle O Rove, Thomas W Flaig
Current Drug Targets|June 6, 2015
The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial CarcinomaMaria T Bourlon, Thomas W Flaig
Pageof 15